Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Update Ferrum Resources Topa Applications

24 Nov 2011 10:55

RNS Number : 7135S
Emerging Metals Limited
24 November 2011
 



For Immediate Release: 24 November 2011

 

Emerging Metals Limited

("EML" or the "Company")

 

Update on Ferrum Resources Limited

Topa Applications

 

 

Further to the announcement made on 15 September 2011, EML would like to provide an update on its 37.23 per cent associated company Ferrum Resources Limited ("Ferrum").

 

In May 2010, Ferrum, through a wholly owned subsidiary, applied for two exploration permits for iron ore in the Topa Iron Ore Belt in the Central African Republic (the "Topa Applications"). The area under the Topa Applications is subject to current precious metal rights held by AXMIN Inc. ("AXMIN"), a company traded on the TSX Venture Exchange. In March 2010, AXMIN transferred the iron ore rights on the property to Ferrum in exchange for a 25 per cent. participating interest in the project once the exploration permits have been granted and notified the Minister of Mines of this transfer of iron ore rights on the property.

 

Ferrum was informed by letter dated 12 September 2011 that the Topa Applications had been denied since the application area (the "Licence Area") was stated to be covered by an exploration licence for the same mineral, iron, granted to a third party. Ferrum, which notified EML of the apparent rejection on 13 October 2011, believes that the Topa Applications were validly submitted and that it has a priority right to be granted exploration permits for iron in the Licence Area. It has accordingly made representations to and held discussions with the Government of the Central African Republic with a view initially to the denial of the Topa Applications being revoked. Whilst these discussions have been positive, there can be no certainty at this stage that the denial will be revoked or that the Topa Applications will thereafter be approved.

 

The Company will update its shareholders as and when there are further developments regarding the Topa Applications.

 

As previously announced, EML holds an option to acquire all of the issued and to be issued share capital of Ferrum which it does not already own.

 

For further information:

 

Emerging Metals Limited

Religare Capital Markets Limited

Evolution Securities Limited

GTH Communications

Denham Eke

Peter Trevelyan-Clark

Emily Staples

 

Mark Wellesley-Wood

Tim Redfern

 

Toby Hall

+44 (0) 1624 639396

+44 (0) 20 7444 0800

+44 (0)20 7071 4300

+44 (0) 20 3103 3902

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBIBMTMBATBJB
Date   Source Headline
19th May 20238:00 amRNSADS Program collapse
15th May 20237:00 amRNSChange of Record Time and Last Day of Dealings
11th May 202312:00 pmRNSWebull Corporate Communications Service Platform
11th May 20237:00 amRNSChange of Delisting Date to 22 May 2023
3rd May 20231:00 pmRNSResult of Meeting
3rd May 20237:00 amRNSPresentation on OK-101 at ASCRS
2nd May 20237:00 amRNSFirst-Patient First-Visit for Phase 2 Trial
25th Apr 20237:00 amRNSActivation of First Clinical Trial Site in the U.S
5th Apr 20237:00 amRNSNOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION
4th Apr 20237:00 amRNSNotice Of Intention To Delist From The LSE
30th Mar 20237:00 amRNSDirector Acquires Shares
29th Mar 20237:00 amRNSDirector acquires shares
24th Mar 20237:00 amRNSDirector/PDMR Shareholding
16th Mar 20237:01 amRNSListing of Trial on the ClinicalTrials.gov Website
16th Mar 20237:00 amRNSClosing of Global Private Placement
15th Mar 20237:01 amRNSDirector/PDMR Dealings
14th Mar 20237:00 amRNSIssue of Equity
13th Mar 20233:16 pmRNSCEO Interview
6th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSCustom Clearance of GMP Packaged OK-101 Drug
23rd Feb 20237:00 amRNSAppointment to Scientific Advisory Board
21st Feb 20237:00 amRNSCorporate Presentation
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20232:05 pmRNSSecond Price Monitoring Extn
20th Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 202311:05 amRNSSecond Price Monitoring Extn
20th Feb 202311:00 amRNSPrice Monitoring Extension
20th Feb 20239:05 amRNSSecond Price Monitoring Extn
20th Feb 20239:00 amRNSPrice Monitoring Extension
17th Feb 20234:40 pmRNSSecond Price Monitoring Extn
17th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSAllotment of Shares and Total Voting Rights
10th Jan 20234:40 pmRNSSecond Price Monitoring Extn
10th Jan 20234:35 pmRNSPrice Monitoring Extension
10th Jan 20232:05 pmRNSSecond Price Monitoring Extn
10th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 20231:15 pmRNSInterim Results - availability
30th Dec 20227:00 amRNSInterim Results for the Six Months Ending 30Sept22
22nd Dec 20227:00 amRNSU.S. FDA Clearance of IND Application for OK-101
21st Dec 20227:00 amRNSOKYO to Participate at Biotech Showcase
6th Dec 20227:00 amRNSOKYO files a registration statement with the SEC
1st Dec 20227:00 amRNSChange of Auditor
24th Nov 20227:00 amRNSDirector/PDMR Shareholding
21st Nov 20227:00 amRNSU.S. IND Filing on OK-101 for the Treatment of DED
20th Oct 20227:00 amRNSOKYO to participate at 2022 ThinkEquity Conference
8th Sep 20222:30 pmRNSOKYO interview on Bloomberg: RedChip Money Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.